PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis
USA - NYSE:PBH - US74112D1019 - Common Stock
59.17 USD
+0.68 (+1.16%)
59.17 USD
0 (0%)
PBH gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. PBH scores excellent points on both the profitability and health parts. This is a solid base for a good stock. PBH has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
PBH had positive earnings in the past year.
In the past year PBH had a positive cash flow from operations.
PBH had positive earnings in 4 of the past 5 years.
PBH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 6.21%, PBH belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
The Return On Equity of PBH (11.48%) is better than 86.46% of its industry peers.
The Return On Invested Capital of PBH (7.95%) is better than 85.94% of its industry peers.
PBH had an Average Return On Invested Capital over the past 3 years of 8.16%. This is significantly below the industry average of 13.48%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.21% | ||
| ROE | 11.48% | ||
| ROIC | 7.95% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
PBH's Profit Margin of 19.02% is amongst the best of the industry. PBH outperforms 91.15% of its industry peers.
In the last couple of years the Profit Margin of PBH has grown nicely.
With an excellent Operating Margin value of 31.15%, PBH belongs to the best of the industry, outperforming 94.27% of the companies in the same industry.
In the last couple of years the Operating Margin of PBH has remained more or less at the same level.
Looking at the Gross Margin, with a value of 56.13%, PBH is in the better half of the industry, outperforming 65.63% of the companies in the same industry.
PBH's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.15% | ||
| PM (TTM) | 19.02% | ||
| GM | 56.13% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PBH is destroying value.
PBH has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, PBH has less shares outstanding
The debt/assets ratio for PBH has been reduced compared to a year ago.
2.2 Solvency
PBH has an Altman-Z score of 2.54. This is not the best score and indicates that PBH is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.54, PBH is in the better half of the industry, outperforming 67.19% of the companies in the same industry.
The Debt to FCF ratio of PBH is 3.79, which is a good value as it means it would take PBH, 3.79 years of fcf income to pay off all of its debts.
PBH has a better Debt to FCF ratio (3.79) than 85.42% of its industry peers.
PBH has a Debt/Equity ratio of 0.55. This is a neutral value indicating PBH is somewhat dependend on debt financing.
PBH's Debt to Equity ratio of 0.55 is on the low side compared to the rest of the industry. PBH is outperformed by 64.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.79 | ||
| Altman-Z | 2.54 |
ROIC/WACC0.96
WACC8.31%
2.3 Liquidity
PBH has a Current Ratio of 4.38. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 4.38, PBH is doing good in the industry, outperforming 63.54% of the companies in the same industry.
A Quick Ratio of 2.99 indicates that PBH has no problem at all paying its short term obligations.
PBH's Quick ratio of 2.99 is in line compared to the rest of the industry. PBH outperforms 54.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.38 | ||
| Quick Ratio | 2.99 |
3. Growth
3.1 Past
PBH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.15%, which is quite good.
The Earnings Per Share has been growing by 8.88% on average over the past years. This is quite good.
Looking at the last year, PBH shows a small growth in Revenue. The Revenue has grown by 1.10% in the last year.
Measured over the past years, PBH shows a small growth in Revenue. The Revenue has been growing by 3.39% on average per year.
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
Revenue 1Y (TTM)1.1%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
3.2 Future
PBH is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.45% yearly.
Based on estimates for the next years, PBH will show a small growth in Revenue. The Revenue will grow by 1.11% on average per year.
EPS Next Y0.67%
EPS Next 2Y3.17%
EPS Next 3Y2.82%
EPS Next 5Y3.45%
Revenue Next Year-2.36%
Revenue Next 2Y0.13%
Revenue Next 3Y0.46%
Revenue Next 5Y1.11%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 12.98, PBH is valued correctly.
Based on the Price/Earnings ratio, PBH is valued cheaper than 87.50% of the companies in the same industry.
PBH is valuated rather cheaply when we compare the Price/Earnings ratio to 25.07, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 12.27 indicates a correct valuation of PBH.
PBH's Price/Forward Earnings ratio is rather cheap when compared to the industry. PBH is cheaper than 84.90% of the companies in the same industry.
PBH is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.08, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.98 | ||
| Fwd PE | 12.27 |
4.2 Price Multiples
PBH's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PBH is cheaper than 88.02% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, PBH is valued cheaply inside the industry as 88.54% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.87 | ||
| EV/EBITDA | 9.91 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PBH has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)19.33
PEG (5Y)1.46
EPS Next 2Y3.17%
EPS Next 3Y2.82%
5. Dividend
5.1 Amount
No dividends for PBH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
59.17
+0.68 (+1.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners107.07%
Inst Owner Change-0.69%
Ins Owners1.29%
Ins Owner Change1.87%
Market Cap2.91B
Revenue(TTM)1.14B
Net Income(TTM)213.00M
Analysts84
Price Target82.42 (39.29%)
Short Float %3.12%
Short Ratio3.32
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.66%
Min EPS beat(2)-5.96%
Max EPS beat(2)0.64%
EPS beat(4)2
Avg EPS beat(4)-0.37%
Min EPS beat(4)-5.96%
Max EPS beat(4)4.3%
EPS beat(8)4
Avg EPS beat(8)-1.59%
EPS beat(12)7
Avg EPS beat(12)-47.18%
EPS beat(16)11
Avg EPS beat(16)-34.2%
Revenue beat(2)1
Avg Revenue beat(2)-1.94%
Min Revenue beat(2)-5.34%
Max Revenue beat(2)1.46%
Revenue beat(4)2
Avg Revenue beat(4)-0.99%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)1.46%
Revenue beat(8)3
Avg Revenue beat(8)-0.96%
Revenue beat(12)5
Avg Revenue beat(12)-0.52%
Revenue beat(16)9
Avg Revenue beat(16)0.45%
PT rev (1m)-3.35%
PT rev (3m)-10.02%
EPS NQ rev (1m)0.01%
EPS NQ rev (3m)-9.33%
EPS NY rev (1m)-0.25%
EPS NY rev (3m)-5.34%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)-2.43%
Revenue NY rev (1m)-0.18%
Revenue NY rev (3m)-3.96%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.98 | ||
| Fwd PE | 12.27 | ||
| P/S | 2.6 | ||
| P/FCF | 10.87 | ||
| P/OCF | 10.56 | ||
| P/B | 1.57 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.91 |
EPS(TTM)4.56
EY7.71%
EPS(NY)4.82
Fwd EY8.15%
FCF(TTM)5.44
FCFY9.2%
OCF(TTM)5.6
OCFY9.47%
SpS22.76
BVpS37.71
TBVpS-19.66
PEG (NY)19.33
PEG (5Y)1.46
Graham Number62.2
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.21% | ||
| ROE | 11.48% | ||
| ROCE | 10.5% | ||
| ROIC | 7.95% | ||
| ROICexc | 8.3% | ||
| ROICexgc | 73.5% | ||
| OM | 31.15% | ||
| PM (TTM) | 19.02% | ||
| GM | 56.13% | ||
| FCFM | 23.91% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexgc growth 3Y-14.1%
ROICexgc growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score8
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.79 | ||
| Debt/EBITDA | 2.67 | ||
| Cap/Depr | 26.62% | ||
| Cap/Sales | 0.71% | ||
| Interest Coverage | 7.65 | ||
| Cash Conversion | 72.82% | ||
| Profit Quality | 125.75% | ||
| Current Ratio | 4.38 | ||
| Quick Ratio | 2.99 | ||
| Altman-Z | 2.54 |
F-Score8
WACC8.31%
ROIC/WACC0.96
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
EPS Next Y0.67%
EPS Next 2Y3.17%
EPS Next 3Y2.82%
EPS Next 5Y3.45%
Revenue 1Y (TTM)1.1%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
Revenue Next Year-2.36%
Revenue Next 2Y0.13%
Revenue Next 3Y0.46%
Revenue Next 5Y1.11%
EBIT growth 1Y5.97%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year7.03%
EBIT Next 3Y3.48%
EBIT Next 5Y2.99%
FCF growth 1Y26.73%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y25.6%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%
PRESTIGE CONSUMER HEALTHCARE / PBH FAQ
What is the ChartMill fundamental rating of PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PBH.
What is the valuation status for PBH stock?
ChartMill assigns a valuation rating of 6 / 10 to PRESTIGE CONSUMER HEALTHCARE (PBH). This can be considered as Fairly Valued.
How profitable is PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
PRESTIGE CONSUMER HEALTHCARE (PBH) has a profitability rating of 7 / 10.
How financially healthy is PRESTIGE CONSUMER HEALTHCARE?
The financial health rating of PRESTIGE CONSUMER HEALTHCARE (PBH) is 7 / 10.
What is the earnings growth outlook for PRESTIGE CONSUMER HEALTHCARE?
The Earnings per Share (EPS) of PRESTIGE CONSUMER HEALTHCARE (PBH) is expected to grow by 0.67% in the next year.